Clinical Trial Update: A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment [Phase 4]

View source ↗

Summary

Phase 4 study evaluating enzalutamide re-treatment in metastatic castration-resistant prostate cancer after prior docetaxel and/or cabazitaxel treatment was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 4 | Status: TERMINATED | Results posted: 2018-04-19